Also known as Zetia and Ezetrol.
Pre‑specified VESALIUS‑CV analysis shows evolocumab plus background therapy lowers deaths and major CV events in high‑risk adults without prior MI/stroke.
VESALIUS‑CV subgroup shows evolocumab lowers first major cardiovascular events and LDL‑C; real‑world GLP‑1 persistence is low, curbing potential benefits.
VESALIUS‑CV subgroup (3,655 high‑risk diabetics without known atherosclerosis) showed a 31% reduction in first major CV events vs placebo; median LDL‑C 44 mg/dL over ~4.8 years.
